Novavax Inc. (NVAX)
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Novavax (NVAX) closed the most recent trading day at $8.46, moving 1.51% from the previous trading session.
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights
Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) closed the most recent trading day at $9.08, moving 4.02% from the previous trading session.
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Novavax (NVAX) settling at $8.67, representing a +1.17% change from its previous close.
Here's Why Novavax (NVAX) Fell More Than Broader Market
Novavax (NVAX) closed at $8.39 in the latest trading session, marking a -1.99% move from the prior day.
Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript
Novavax, Inc. (NASDAQ:NVAX ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Pete Stavropoulos - Cantor Presentation Pete Stavropoulos Welcome to the Cantor Global Healthcare Conference. I am Pete Stavropoulos, biotech analyst at Cantor.
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO & Director Luis Sanay - Corporate Participant Ruxandra Draghia-Akli - Executive VP and Head of Research & Development Silvia Taylor - Corporate Participant Conference Call Participants Alec Warren Stranahan - BofA Securities, Research Division Christopher Hue LoBianco - TD Cowen, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Roger Song - Jefferies LLC, Research Division Thomas Eugene Shrader - BTIG, LLC, Research Division Operator Good morning, and welcome to Novavax Second Quarter 2025 Financial Results and Operational Highlights Conference Call.
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
Novavax (NVAX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to earnings of $0.99 per share a year ago.
Novavax beats quarterly revenue estimates on milestone payment
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
